Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the tolerability and efficac...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Huls, Gerwin, Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J. M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, van Zeventer, Isabelle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W. M., Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2020
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509861/
https://ncbi.nlm.nih.gov/pubmed/32915972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002846
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍